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Immunotherapy with the use of rationally designed 
cancer vaccines is presently considered as a promising 
approach for cancer treatment directed on enhancement 
of immune response against specific antigens expressed 
in tumor cells. As a rule, tumor antigens are poorly immu-
nogenic, that’s why vaccination with tumor-associated 
antigens (TAAs) only doesn’t lead to induction of effective 
antitumor immunity. For generation of effective antitumor 
response it is considered reasonable to enhance it via 
introduction of specific chemokine molecules used in 
vaccine formulation as TAA carriers to antigen-presenting 
cells [1–3]. In the last years, along with a number of che-
mokines (CCL7, CCL20, CXCL10 etc.), an antimicrobial 
peptide murine beta-defensin-2 (mBD-2), a molecule 
which ability to bind CCR6 on iDCs [4], has been used 
in experimental cancer immunotherapy as the carrier of 
genetically fused TAA, what improved significantly the 
clinical efficacy of the vaccinations [5–7]. In the pres-
ent research devoted to experimental cancer vaccine 
therapy, taking into account the data of immunologic 
studies [5–7], we have chosen mBD-2 as a chemokine 
in the content of cancer vaccines; from the other side we 
wish to explore whether activation of in vivo expression of 
this peptide antibiotic may be beneficial for clinical effect 
of cancer immunotherapy.
mBD-2 belongs to the family of small (2–6 kD) 
cationic microbicidal peptides that are produced by 
epithelial cells in response to bacterial products and 
proinflammatory cytokines, possess multiple biologic 
activities, in particular immunomodulatory ones, and 
compose an important chain of innate immunity sys-
tem [8, 9]. Moreover, similarly to other mammalian 
defensins [10–12], mBD-2 may be involved in tumori-
genesis playing a complex and poorly understood yet 
role in cancer cells and tumor microenvironment. Ac-
cording to our recent results [12], mBD-2 expressed 
in murine Lewis lung carcinoma (3LL) cells, may pos-
sibly be involved in regulation of 3LL cell proliferation 
in vitro and in vivo playing antiproliferative role in this 
experimental tumor. Down-regulation of mBD-2 mRNA 
expression in 3LL cells in vivo led to accelerated tumor 
growth and more aggressive metastasis [12]. There-
fore, we hypothesized that up-regulation of mBD-
2 expression in epithelial tissues of 3LL-bearing mice 
in addition to immunotherapy could improve total an-
ticancer effect of the treatment. In this regard we have 
decided to analyze whether it is possible to activate 
mBD-2 mRNA expression in vivo by introduction of vi-
tamin D3 (VD3) to experimental animals. According to 
the literature data, some human antimicrobial peptides 
(cathelicidin [13] and human beta-defensin-2 [14]) are 
positively regulated by 1.25(OH)2D3 — metabolic form 
of VD3. The study [15] performed on mice has shown 
that mBD-2, mBD3 and cathelin-related antimicrobial 
peptide are up-regulated in mouse skin exposed to 
low-dose UV irradiation, and this process is mediated 
by cutaneous VD3 activation.
To our knowledge, despite wide interest to VD3 as 
potent pleiotropic immunomodulating agent that may 
be used alone or in combination with chemothera py 
[16] significantly improving anticancer effect of treat-
ment, there are just few publications in the field on its 
combined use in a setting of cancer immunotherapy. 
For example, in the work [17], the research has been 
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performed on 3LL model, where the efficacy of applied 
immunotherapy (adoptively transferred tumor-reactive 
lymph node cells) has been shown to be significantly 
elevated by introduction of VD3; the authors have 
registered the significant antimetastatic effect of such 
treatment. In a series of works [18–20] it has been 
demonstrated that VD3/calcitriol may be considered 
an effective mucosal adjuvant agent potently promot-
ing immune responses to cutaneously administered 
vaccines.
So, the first task of our work was to study the ex-
pression patterns of mBD-2 mRNA in lung tissue of 
healthy mice treated with VD3, and the second one 
was to prepare anticancer protein-based and DNA-
based vaccines and analyze whether their efficacy 
in vivo in 3LL tumor model may be increased by an 
introduction of VD3.
MATERIALS AND METHODS
Cell lines and bacterial strains. In vitro culture of 
transplantable 3LL cells was obtained from the Bank of 
Cell Lines from Human and Animal Tissues of R.E. Ka-
vetsky Institute of Experimental Pathology, Oncology 
and Radiobiology, NAS of Ukraine (Kyiv, Ukraine). The 
cells were cultivated in vitro in DMEM culture medium 
with high glucose content supplemented with 10% 
fetal bovine serum, 100 units/mL penicillin, 100 μg/mL 
streptomycin sulfate, and 0.25 μg/mL amphotericin B 
as fungizone in 5% CO2 athmosphere at 37 °C.
Cultivation of bacterial cells (strain E. coli DH5α) 
was carried out on LB medium at 37 °C. Selection and 
storage of recombinant colonies was performed on 
agarized LB medium supplemented with 50 μg/mL 
ampicilline or kanamycine.
Gene cloning and plasmid construction. The 
pcDNA3-Igk-mBD-2 expression plasmid contai-
ning secretable mBD-2 was created by the following 
way. Mouse Igk signal sequence was cloned from 
plasmid pSecTag2a to pcDNA3.1.+. Gene for ma-
ture mBD2 was obtained from lipopolysaccharide 
(10 ng/ml)-treated murine BALB/c macrophages 
by RT-PCR using the following primers: mBD-2-F: 
5’-ACCTAAGCTTCGAACTTGACCACTGCCACACC-3’ 
and mBD-2-R: 5’-GCCGAATTCTCATTTCATGTACTT-
GCAACAGGG-3. The mature mBD2 cDNA was cloned 
in frame with Igk signal sequence.
For construction of pcDNA3-Igk-mBD-2-Muc1, ex-
tracellular domain of Muc1 fragment containing 11 tan-
dem repeats was cloned by RT-PCR from total RNA 
of 3LL cells with the use of the following PCR pri mers: 
Muc1-F: 5’-GCCGAATTCACCAGCAGTTCCTTAG-
CATC-3’; Muc1-R: 5’-CTACTCGAGTCATGCAGAGCT-
GGTAGTTGTGAC-3’; and for mBD-2 fragment: 
mBD-2-F and CmBD-R: 5’-GGCGAATTCAAGATCG-
GCTTTCATGTACTTGCAACAGGG-3’. The N-terminus 
of Muc1 was fused in frame with mBD-2 through the 
linker sequence. The Muc1 fragment for the control 
vector pcDNA3-Igk-Muc1 was amplified using the 
following primers pair: CMuc1-F: 5’-AACAAGCTTCAC-
CAGCAGTTCCTTAGCATC -3’; Muc1-R.
All constructs were verified by DNA dideoxyse-
quencing method using T7 and BGH primers and puri-
fied using plasmid purification kit Quiagen EndoFree 
(USA). Content of LPS in plasmid preparation and pro-
tein-based vaccine was evaluated by standard LAL-test.
Control transfection of human embryonal kidney 
(HEK293) cells was performed with the use of FuGene 
6 reagent (Roche Molecular Biochemicals, USA) ac-
cording to the instructions of the manufacturer.
RT-PCR analysis. Total RNA was isolated from tis-
sue samples by the method of Chromzynski and Sacchi 
[21]. For detection of mBD-2 or Muc1 RNA expression, 
semiquantitative RT-PCR analysis was performed 
with the use of specific primers. The expression level 
of beta-actin as the house-keeping gene served as 
a control. The relative expression level was analyzed 
with the use of TotalLab Program.
Preparation of protein-based vaccine. For the 
preparation of protein-based vaccine, active recombi-
nant mBD-2 produced in bacterial cells as GST-fusion 
protein [12], that was additionally purified from endo-
toxin contaminants has been used. 3LL cell lysate was 
prepared from in vitro cultured 3LL cells by standard 
lysis of the cells with modified SDS-free RIPA buffer, 
and stored at –70 °C until use.
In vivo study. For in vivo research, male C57Bl 
mice 2 months old bred in the animal facility of R.E. Ka-
vetsky Institute of Experimental Pathology, Oncology 
and Radiobiology, NAS of Ukraine (Kyiv, Ukraine) were 
used. All animal procedures were carried out accor-
ding to the rules of local Ethic Committee and were 
approved by the Ethic Board of IEPOR NASU.
3LL cells (5 x 104 cells/100 μl PBS per animal) were 
transplanted i.m. in right hind leg of C57Bl mice. Tu-
mor growth dynamics was monitored each 5 days by 
means of calipers starting from day 17 after tumor cell 
transplantation when tumors became palpable, and till 
the end of experiment. At 34-th day after tumor cell 
transplantation, the animals were sacrificed by ether 
narcosis, primary tumors and lungs were removed and 
weighted, lung metastases were calculated, and blood 
serum was collected.
Immunotherapy of experimental murine tumors 
with the use of cancer DNA vaccine or protein-based 
vaccine was performed at therapeutic and prophy-
lactic regimens by similar schedules. In therapeutic 
setting, vaccine was introduced i.d. at days 2, 6, 10, 
and 20 after tumor cell transplantation [5]; in prophy-
lactic one — at days 0, 4, 8, 18; in 2 weeks after the 
last immunization, 3LL cells were transplanted. For 
i.d. administration of DNA vaccine, the first three im-
munizations (20 μg DNA/10 μL PBS) were performed 
with the use of tattoo device in the skin of left hind leg 
by the method described in [22], while the fourth vac-
cination (20 μg DNA/10 μL PBS) was done i. d. in the 
ear of animals. In the case of protein-based cancer 
vaccine, it was injected i. d. only in the ear of animals 
(recombinant mBD-2 peptide (2 g/10 l PBS) and 
3LL cell lysate (20 g/20 l PBS)).
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VD3 (10 IU/day/animal) was administered with 
drinking water. Cyclophosphamide (СР, 2.5 mg/100 μL 
PBS/animal) was administered i. p. at the days 1, 9, 
19 after tumor cell transplantation as described in [23].
Experimental animals were housed in 10 groups 
per each protein-based vaccination setting (А — thera-
peutic regimen, B — prophylactic regimen; n = 5 per 
group) and received the following treatment: А1 (B1) — 
control; А2 — mBD-2; А3 — 3LL cell lysate; А4 — 
3LL + VD3; A5 — 3LL + D3 + CP; A6 — mBD-2 + 3LL; 
А7 — VD3; А8 — СР; А9 — mBD-2 + 3LL + VD3; А10 — 
mBD-2 + 3LL + VD3 + СР.
Similarly, for DNA-vaccination there were 10 groups 
for therapy (C) and 10 groups for prophylaxis (D)
(n = 5 per group) that received complete or incom-
plete plasmid constructs: C1 (D1) — control (blank 
vector); C2 (D2) — pcDNA3-Igk-mBD-2; C3 (D3) 
–pcDNA3-Igk-Muc1; C4 (D4) — pcDNA3-Igk-Muc1 
+ VD3; C5 (D5) — pcDNA3-Igk-Muc1 + VD3 +CP; C6 
(D6) — pcDNA3-Igk-mBD-2-Muc1; C7 (D7) — VD3; 
C8 (D8) — CP; C9 (D9) — pcDNA3-Igk-Muc1 + VD3; 
C10 (D10) — pcDNA3-Igk-mBD-2-Muc1 + VD3 + СР.
Antitumor and antimetastatic effects of vaccina-
tion were evaluated by suppression of primary tumor 
growth and the number of lung metastases. Each 
experiment was repeated twice.
Statistical analysis. The data were reported as the 
mean  SD. The statistical significance of the differen ces 
between mean values was assessed by the Student’s 
t-test. Values p < 0.05 were considered statistically 
significant. Differences in survival between the groups 
were determined by nonparametric log-rank test.
RESULTS AND DISCUSSION
VD3 treatment up-regulates mBD-2 mRNA 
expression in murine lung tissue. Prior to vaccina-
tions, we have performed an in vivo study in order to 
analyze whether it is possible to activate mBD-2 mRNA 
expression in vivo in epithelial lung cells of healthy mice 
by introduction of VD3. Experiment has been carried 
out on healthy C57Bl male mice (n = 3 per group) 
that received VD3 (10 IU per animal per day) per os 
for 10 days, or did not receive the vitamin. Then the 
animals were sacrificed, and mBD-2 mRNA expression 
level in healthy lung tissues of the animals was ana-
lyzed with the use of semiquantitative RT-PCR analysis. 
Our data have demonstrated (Fig. 1) that consumption 
of VD3 resulted in up-regulation of mBD-2 expression 
in healthy lungs of C57Bl mice compared to the con-
trol. So, we have expected that introduction of VD3 in 
immunotherapy schedule may lead to up-regulation 
of mBD-2 expression in lung tissues of experimental 
animals and, respectively, to elevation of its local an-
tiproliferative activity [12] what may possibly improve 
the results of experimental immunotherapy.
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Fig. 1. RT-PCR analysis of mBD-2 mRNA expression in lung 
tissue of healthy mice (a): mBD-2 mRNA expression in lungs 
of healthy animals that were treated with VD3 (line 4) vs that in 
control animals (line 3). Graphical representation of mBD2 mRNA 
expression level normalized by beta-actin expression (b)
Design of experiment and selection of tumor 
model. For performance of vaccinations, we have 
used 3LL, an experimental model of murine solid tumor 
with high level metastasis in lungs. Transplantation of 
just 5 x 104 3LL cells/animal results in 100% lethality 
in 5 weeks period.
In a setting of protein-based vaccine, we have used 
3LL cell lysate as total tumor antigen.
In a setting of DNA-based vaccine, to select 
a protein target in 3LL cells, we have performed an 
analysis of literature data in the field, and decided to 
introduce murine mucin-1 (Muc1) coding sequence in 
DNA vaccine. Muc1 is a highly glycosylated 200 kDa 
membrane protein [24], a non-polymorphic homo-
log of human polymorphic epithelial mucin MUC1. 
The human MUC1 is expressed by a wide variety of 
epithelial tissues where the protein plays the important 
physiologic and antiinflammatory roles at normal state 
[25, 26]. In human epithelial cancers, MUC1 is often 
overexpressed, underglycosylated and lost polarized 
type of expression, that’s why it is recognized as uni-
versal tumor antigen of human carcinoma. There are 
numerous experimental researches of cancer vaccines 
directed against MUC1 performed on MUC1-transgenic 
animals, and clinical trials of cancer vaccines directed 
against MUC1 [27, 28]; and their results are promising. 
In contrary, little is known about expression patterns of 
Muc1 in murine tumors, and experimental vaccinations 
with the use of wtMuc1 have been done rarely. Accor-
ding to the data of literature [29], earlier with the use 
of experimental breast cancer model there were per-
formed immunizations in C3H/HeOuj mice with mouse 
mucin-1 fusion protein, and in a case of combination 
of such immunotherapy with CP treatment antitumor 
effect has been registered. As far as we did not found 
the data on Muc1 expression patterns in murine tumor 
cells and in particular, in 3LL cells, we have performed 
semiquantitative RT-PCR analysis of Muc1 mRNA 
expression in 3LL-derived tumors, healthy lungs and 
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heavily metastasized lungs of 3LL-bearing mice. We 
have registered high expression levels of Muc1 mRNA 
both in 3LL derived tumors, metastatic lesions, and 
in healthy lung cells of C57Bl mice (Fig. 2); so, being 
certain that Muc1 is expressed in 3LL cells, we have 
supposed to direct our vaccine against Muc1 in this 
particular tumor model despite the understandable risk 
of its low specificity and autoimmunity.
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Fig. 2. RT-PCR analysis of Muc1 mRNA expression in largely 
metastasized murine lung tissue (line 4), healthy lung tissue 
(lines 1, 2) and primary 3LL tumor sample (line 3). Expression 
of beta-actin served as a control (a). Graphical representation 
of mBD2 mRNA expression level normalized by beta-actin ex-
pression (b)
At last, according to literature data [23, 30], cancer 
immunotherapy efficacy could be elevated by its com-
bination with low-dose chemotherapy for inhibition of 
immunosuppressive cancer network. That’s why we 
have supplemented the vaccination schedule with 
low-dose CP therapy (100 mg/kg).
Vaccination of 3LL-bearing mice with cancer 
vaccine composed from recombinant mBD-2 pep-
tide and 3LL cell lysate. To analyze antitumor effect 
of vaccination with the use of cancer vaccine com-
posed from recombinant mBD-2 peptide (2 g/10 l 
PBS) and 3LL cell lysate (20 g/20 l PBS), we have 
applied both therapeutic and prophylactic administra-
tion of the vaccine and its separate components with or 
without VD3 and CP therapy by the schemes described 
in Materials and Methods section.
The results of therapeutic vaccination have shown 
(Fig. 3, 4) that administration of mBD-2 peptide to-
gether with 3LL cell lysate led to statistically insignifi-
cant suppression of primary tumor growth and meta-
static levels in 3LL-bearing mice compared with control 
groups. However, introduction of VD3 into treatment 
schedule, especially in combination with CP therapy at 
metronomic regimen, has notably affected an efficacy 
of such vaccination and resulted in significant decrease 
of primary tumor volumes (group A10, p < 0.005, see 
Fig. 3) and the number of lung metastases (see Fig. 4). 
Interestingly, similar antimetastatic effect of VD3 ad-
ministration has been observed in a control group of 
animals treated with 3LL cell lysate + VD3 (see Fig. 4) 
but not in the case of separate VD3 or 3LL cell lysate 
administration, and there were insignificant differences 
in lung metastasis numbers bet ween 3LL + VD3 and 
mBD-2 + 3LL + VD3 treated groups. Administration of 
CP only didn’t influence significantly primary tumor 
volumes, but had significant antimetastatic effect 
(group A8). Upon prophylactic administration of the 
vaccine, also the highest antimetastatic effect has been 
observed in the case of administration of the vaccine si-
multaneously with VD3 consumption (mean lung weight 
in vaccine + VD3 treated animals was 190 ± 15 mg vs 
295 ± 145 mg in control groups). Both prophylactic and 
therapeutic vaccinations had statistically insignificant 
influence on average life span of tumor-bearing mice 
(Fig. 5).
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Fig. 3. Comparative analysis of primary tumor weight (rel. units) 
in experimental animals from groups A1–A10 treated with pro-
tein-based vaccine at therapeutic regimen at the day 34 after 3LL 
transplantation: А1 — control; А2 — mBD-2; А3 — 3LL cell lysate; 
А4 — 3LL + VD3; A5 — 3LL + D3 + CP; A6 — mBD-2 + 3LL; А7 — 
VD3; А8 — СР; А9 — mBD-2 + 3LL + VD3; А10 — mBD-2 + 3LL + 
VD3 + СР. Each group was composed from 5 animals, experi-
ment was twice repeated. *Difference is significant (p < 0.005) 
compared to group A1.
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Fig. 4. Lung weight of experimental animals from groups A1–
A10 treated with protein-based vaccine at therapeutic regimen 
at the day 34 after 3LL transplantation. Treatment groups: А1 — 
control; А2 — mBD-2; А3 — 3LL cell lysate; А4 — 3LL + VD3; 
A5 — 3LL + D3 + CP; A6 — mBD-2 + 3LL; А7 — VD3; А8 — СР; 
А9 — mBD-2 + 3LL + VD3; А10 — mBD-2 + 3LL + VD3 + СР. 
Each group was composed from 5 animals, experiment was 
twice repeated
So, from the data of mentioned above experiments 
we have figure out two main conclusions. Firstly, an 
anticancer efficacy of protein [mBD-2 + 3LL lysate] 
vaccination is moderate enough and did not generate 
significant therapeutic and protective immunity in 3LL 
model. Such results could be explained by the data of 
investigation [4] where the authors have shown that 
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effective vaccinations using beta-defensin-2 require 
an existence of physical link between peptide and TAA 
to elicit antitumor immunity. Possibly, an absence of 
chemical coupling between recombinant mBD-2 pep-
tide and TAAs in 3LL cell lysate may explain mode rately 
good results of vaccination of 3LL bearing mice. Sec-
ondly, our results have demonstrated that introduction 
of VD3 into the scheme of cancer immunotherapy may 
be considered reasonable and, without being toxic, 
notably elevates antimetastatic effect of vaccination, 
even in its defensin-free setting (see Fig. 4). Besides, 
the use of VD3 alone also led to some decrease of 
secondary tumors volumes, however such rates were 
statistically insignificant; it couldn’t be excluded that 
mentioned effect may be in part realized via up-regu-
lation of mBD-2 gene in murine epithelial tissues. Both 
mentioned conclusions we have taken into account in 
the second part of our research directed on generation 
of mBD-2-containing cancer DNA vaccine.
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Fig. 5. Survival of 3LL-bearing mice treated with protein-based 
vaccine at therapeutic (a) and prophylactic (b) regimens. Each 
group of animals was composed from 10 animals. Log-rank 
test. Treatment groups: А1 (B1) — control; А2 (B2) — mBD-2; 
А3 (B3) — 3LL cell lysate; А4 (B4) — 3LL + VD3; A5 (B5) — 3LL + 
D3 + CP; A6 (B6) — mBD-2 + 3LL; А7 (B7) — VD3; А8 (B8) — 
СР; А9 (B9) — mBD-2 + 3LL + VD3; А10 (B10) — mBD-2 + 3LL + 
VD3 + СР. *Difference is significant (p < 0.05) compared to the 
control groups treated with blank vector.
Construction of cancer DNA vaccine composed 
from mBD-2 and murine Muc1. To generate cancer 
DNA vaccine composed from mBD-2 and murine 
Muc1, we have constructed DNA vector — chimeric 
molecule containing the coding sequences of mature 
mBD-2 and murine Muc1 genes by the procedure 
described in Materials and Methods section.
The constructs were tested by control transfec-
tion of human embryonal kidney HEK293 cells, with 
the next RT-PCR analysis of Muc1 mRNA expres-
sion (Fig. 6). RT-PCR analysis has demonstrated 
that transfection was effective, and the transfected 
HEK293 cells express Muc1 mRNA (see Fig. 6).
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Fig. 6. RT-PCR analysis of Muc1 mRNA expression in control HEK 
293 cells (4) and transfected НЕК-pcDNA3-Igk-Muc1 (5) and 
НЕК-pcDNA3-Igk-mBD-2-Muc1 cells (6). Lines 1–3 — expres-
sion of beta-actin gene in HEK 293, НЕК-pcDNA3Igk-Muc1 and 
НЕК-pcDNA3Igk-mBD-2-Muc1 cells served as a control
So, in following research we have used the next panel 
of vector constructs: pcDNA3.1+, pcDNA3-Igk-mBD-2, 
pcDNA3-Igk-Muc1, pcDNA3-Igk-mBD-2-Muc1.
Evaluation of anticancer efficacy of mBD-2-
Muc1-cancer DNA vaccine. To evaluate anticancer 
efficacy of the developed mBD-2-Muc1-DNA vaccine, 
we have apply vaccination protocol consisting from 
four sequential intradermal immunizations (20 μg 
DNA/10 μl PBS per animal) — first three with the use 
of tattoo device in skin of animal’s leg, and the forth 
one — i. d. in ears of mice, at therapeutic (series C) 
and prophylactic (series D) regimens, as described in 
Materials & Methods section.
As it has been mentioned above, transplantation 
of 5 x 104 3LL cells/animal results in 100% mortality 
in 5 weeks period; as we have found out, vaccination 
with the use of DNA vaccine + VD3 + CP led to genera-
tion of tumor protection in 20% of mice that received 
immunotherapy at prophylactic and therapeutic 
regimens. In the rest of animals that developed the 
tumors, therapeutic vaccination suppressed signifi-
cantly primary tumors growth (p < 0.05) (Fig. 7) and 
led to significant reduction of metastasis (p < 0.005) 
in animals treated with vaccine + VD3 and with/without 
CP (Fig. 8). Prophylactic vaccination led to statistically 
insignificant suppression of primary tumor growth in 
animals treated with vaccine + VD3 + CP and significant 
decrease of metastasis rate in groups D4, D9, D10 
(see Fig. 8); in groups C9, C10, D9 and D10 (pcDNA3-
Igk-mBD-2-Muc1 + VD3 with or without CP) we have 
registered also the significant increase of average 
life-span of tumor-bearing animals (p < 0.05, Fig. 9).
In conclusion, the data of in vivo experiments evi-
dence on positive clinical effect of VD3 introduction 
into scheme of mBD-2-Muc1-DNA-based vaccination 
combined with low-dose CP treatment, reflected in sig-
nificant antimetastatic effect and increase of average 
life-span of tumor-bearing animals. To be explained, 
the aforementioned results, without a doubt, require 
immunological studies, and we’ll perform them in our 
further research.
According to recent knowledge, VD3 is a pleiotropic 
potent regulator of mammalian immune system [30]. 
Its ability to suppress autoimmune reacti vity is dem-
onstrated in experimental models of type 1 diabetes, 
systemic lupus erythematosus, inflammatory bowel 
disease, autoimmune thyroiditis etc. [31, 32]. Along with 
immunosuppressive activity, paradoxically, VD3 has a 
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positive effect as well on the system of innate immunity 
enhancing its response against inva ding microorgan-
isms; VD3 deficiency is believed to be associated with 
susceptibility to some infectious diseases, in particular, 
tuberculosis [33]. In the last case, some possible mecha-
nisms of innate defense against Mycobacterium tuber-
culosis are supposed to be realized via VD3-dependent 
up-regulation of cathelicidin in host macrophages [34]. 
We believe that in present research the favoring effect of 
VD3 on antimetastatic efficacy of experimental cancer 
vaccines possibly may be in some part mediated by 
VD3-dependent up-regulation of mBD-2 in lung epithelial 
cells. Meanwhile, recent publications have shown that 
antitumor activity of VD3 and 1.25(OH)2D3 in vivo, due 
to multiple target genes of the vitamin, could be reali-
zed by many ways including induction of cancer cell 
apoptosis, regulation of the cell cycle, up-regulation 
of VD3-receptor (VDR) playing a role in p53-mediated 
suppression of tumor growth, or regulation of a balance 
between proangiogenic and antiangiogenic factors thus 
influencing tumor angiogenesis [35–37]. Further studies 
in this field will help us understand the mechanisms of 
immunomodulatory effects of VD3 as potentially effec-
tive adjuvant in cancer immunotherapy, and of its direct 
antitumor action.
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Fig. 7. Primary tumors volume (a) and lung weight (b) in 
3LL-bearing mice, treated with DNA vaccine at therapeutic regi-
men at the day 34 after 3LL transplantation: C1 — control (blank 
vector); C2 — pcDNA3-Igk-mBD-2; C3 — pcDNA3-Igk-Muc1; 
C4 — pcDNA3-Igk-Muc1 + VD3; C5 — pcDNA3-Igk-Muc1 + 
VD3 +CP; C6 — pcDNA3-Igk-mBD-2-Muc1; C7 — VD3; C8 — 
CP; C9 — pcDNA3-Igk-mBD-2-Muc1 + VD3; C10 — pcDNA3-
Igk-mBD-2-Muc1 + VD3 + СР. a — *Difference is significant 
(p < 0.05) compared to group C1. b — *Difference is significant 
(p < 0.005) compared to group C1. Each group of animals was 
composed from 5 animals, experiment was twice repeated.
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Fig. 8. Primary tumor volume (a) and lung weight (b) in 3LL-
bearing mice, treated at prophylactic regimen with DNA vaccine 
at the day 34 after 3LL transplantation: D1 — control (blank vec-
tor); D2 — pcDNA3-Igk-mBD-2; D3 — pcDNA3-Igk-Muc1; D4 — 
pcDNA3-Igk-Muc1 + VD3; D5 — pcDNA3-Igk-Muc1 + VD3 + 
CP; D6 — pcDNA3-Igk-mBD-2-Muc1; D7 — VD3; D8 — CP; 
D9 — pcDNA3-Igk-mBD-2-Muc1 + VD3; D10 — pcDNA3-Igk-
mBD-2-Muc1 + VD3 + СР. *Difference is significant (p < 0.05) 
compared to group D1. Each group of animals was composed 
from 5 animals, experiment was twice repeated.
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Fig. 9. Survival of 3LL-bearing mice treated with DNA vaccine 
at therapeutic (a) and prophylactic (b) regimens. Each group 
of animals was composed from 10 animals. Log-rank test. C1 
(D1) — control (blank vector); C2 (D2) — pcDNA3-Igk-mBD-2; 
C3 (D3) — pcDNA3-Igk-Muc1; C4 (D4) — pcDNA3-Igk-Muc1 + 
VD3; C5 (D5) — pcDNA3-Igk-Muc1 + VD3 + CP; C6 (D6) — 
pcDNA3-Igk-mBD-2-Muc1; C7 (D7) — VD3; C8 (D8) — CP; C9 
(D9) — pcDNA3-Igk-mBD-2-Muc1 + VD3; C10 (D10) — pcDNA3-
Igk-mBD-2-Muc1 + VD3 + СР. *Difference between groups C9 vs 
C1, and D9 vs D1 are significant (p < 0.05).
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